ADHD

Four pharmaceutical companies gained approval for atomoxetine (Strattera).

The FDA today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder.

Top news of the day from across the health care landscape.

This article highlights 5 published case reports that document unusually high doses of medications that are not often seen in clinical practice.

A recent study has indicated that even small amounts of exercise can have psychological benefits for adults who experience ADHD symptoms.

Although children and teenagers who are diagnosed with attention-deficit/hyperactivity disorder are more likely to engage in risky behaviors such as dangerous driving and drug use, a recent study has suggested that the use of ADHD medications could help prevent these behaviors.

Metadoxine Extended Release did not meet the primary endpoint in a study analysis for attention deficit hyperactivity disorder.

The drug failed to demonstrate a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).

Mylan launched 2 generic pharmaceutical products at the end of December for the treatment of attention deficit hyperactivity disorder (ADHD) and the prevention of pregnancy.

Students who misuse prescription stimulants to improve their academic performance are more likely to have ADHD.

Mylan's generic version of Dexedrine is now available at US pharmacies in 3 dosage strengths.

The FDA has approved Quillichew ER extended-release chewable tablets for the treatment of ADHD in patients 6 years and older.

Study compare early use and long duration of stimulants versus non-stimulant therapy for ADHD.

Dyanavel XR extended-release oral suspension has received FDA approval for the treatment of ADHD in patients 6 years and older.

Chronic health conditions are on the rise among children, especially those living in poverty.

Children living in extreme poverty with conditions such as asthma or ADHD more likely to have other chronic conditions.

Because of the multifactorial nature and strong genetic component of ADHD, practitioners continue to speculate whether ADHD is due solely to improper brain functioning.

Attention-deficit/hyperactivity disorder has long been viewed as a pediatric condition, but it often lasts into adulthood.

Exposure to antidepressants during pregnancy does not impact a baby's risk for autism or attention-deficit/hyperactivity disorder after birth.

How many of these off-label uses have you seen before?

The FDA has approved Pfizer's chewable formulation of methylphenidate HCl (QuilliChew ER) for the treatment of ADHD in patients 6 years and older.

Mylan has launched a generic version of Teva Pharmaceuticals' Adderall in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 20 mg, and 30 mg doses.

The FDA today approved Tris Pharma's extended-release amphetamine oral suspension (Dyanavel XR) for the treatment of ADHD in children aged 6 years and older.

Young male patients tend to receive antipsychotic prescriptions more often than their female counterparts.

The FDA has added a new warning to the drug label of the methylphenidate transdermal system indicated for ADHD to describe permanent loss of skin color, also known as chemical leukoderma.